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ABSTRACT
We finally have a vaccine for the COVID-19 crisis. However, 
due to the limited numbers of the vaccine, states will 
have to consider how to prioritise groups who receive 
the vaccine. In this paper, we argue that the practical 
implementation of human rights law requires broader 
consideration of intersectional needs in society and the 
disproportionate impact that COVID-19 is having on 
population groups with pre- existing social and medical 
vulnerabilities. The existing frameworks/mechanisms 
and proposals for COVID-19 vaccine allocation have 
shortcomings from a human rights perspective that could 
be remedied by adopting an intersectional allocative 
approach. This necessitates that states allocate the first 
COVID-19 vaccines according to (1) infection risk and 
severity of pre- existing diseases; (2) social vulnerabilities; 
and (3) potential financial and social effects of ill health. In 
line with WHO’s guidelines on universal health coverage, 
a COVID-19 vaccine allocation strategy that it is more 
consistent with international human rights law should 
ensure that vaccines are free at the point of service, give 
priority to the worst off and be allocated in a transparent, 
participatory and accountable prioritisation process.
INTRODUCTION
With over 170 COVID-19 vaccine candidates 
in clinical trials, and several already author-
ised for emergency use, the global commu-
nity is grappling with how to equitably allo-
cate the first available doses of vaccines that 
are proven safe and effective. Clinicians at 
all levels of engagement—from global and 
national health advisors to decision makers 
in health regions and facilities—are being 
confronted with this dilemma. We argue that 
international human rights, which have been 
ratified and are legally binding on 171 states, 
can help in resolving this quandary by inte-
grating an intersectional approach to alloca-
tion processes.
Current allocation frameworks are inad-
equate for fully realising the right to health 
because they overemphasise epidemiolog-
ical concerns.1 An intersectional approach 
to the right to health prioritises population 
groups who experience vulnerability, margin-
alisation and multiple forms of discrimina-
tion. Thus, we argue that vaccine allocation 
frameworks ought to prioritise the needs of 
population groups with pre- existing social, 
health and economic vulnerabilities. We 
argue that an intersectional human rights 
approach provides the best mechanism for 
dealing with overlapping vulnerabilities of 
deprivation, ethnic diversity and (baseline) 
health status, as it considers the social deter-
minants of health and the impact of struc-
tural inequalities.
In this article, we first briefly map the 
current approaches to vaccine allocation, 
before analysing their shortcomings from 
a human rights perspective. We then argue 
that human rights principles are vital when 
allocating scarce healthcare resources 
and what these principles could entail at 
the national level for the first doses of a 
COVID-19 vaccine. Finally, we outline an 
intersectional model of how this could be 
achieved, together with some limitations 
that we foresee in practice.
Summary box
 ► States will continue to be confronted with the ethical 
issue of how to allocate limited supplies of COVID-19 
vaccines that are proven safe and effective as more 
of them become available.
 ► International human rights law requires that ‘vulner-
ability’, if used as a criterion for priority access to 
COVID-19 vaccines, must include social vulnerabil-
ity (eg, socioeconomic status) in addition to medi-
cal vulnerability (eg, comorbidities), and attend to 
intersectionalities.
 ► National vaccine allocation schemes must address 
disparities in health risk and adverse health out-
comes across systematically disadvantaged groups 
when determining COVID-19 vaccine priority groups.
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EXISTING APPROACHES TO COVID-19 VACCINE ALLOCATION
Four main schemes have been proposed for the equi-
table allocation of vaccines (see table 1). The first is 
the COVAX Facility, led by Gavi, the Vaccine Alliance, 
the WHO and the Coalition for Epidemic Preparedness 
Innovations, which intends to purchase vaccines for 
fair distribution across countries.2 At the moment, this 
scheme does not stipulate how national allocation should 
take place. The other three schemes are the WHO/SAGE 
values framework3, the Nuffield Council on Bioethics 
proposal4 and the Fair Priority Model by Emanuel et 
al.5 While the WHO/SAGE values framework mentions 
human rights principles and refers to some of the ‘global 
equity obligations’ of states with regard to vaccine allo-
cation, we argue that the relevant obligations of states 
need further emphasis and clarification to assist states to 
comply with human rights law. Likewise, while the corre-
lation between human rights principles and equitable 
vaccine allocation has been emphasised by the Nuffield 
Council on Bioethics, their meaning and potential for 
practical application have not really been fleshed out. In 
contrast to these, the Fair Priority Model does not explic-
itly mention human rights.
In addition to these four schemes, some countries have 
devised different country- level schemes for vaccine allo-
cation (see table 2). The UK has prioritised older people 
at the expense of other groups, leading for calls to prior-
itise other key groups such as health workers, nursery 
workers and teachers,6 whereas in the USA the focus has 
been on front- line workers. In most jurisdictions, these 
allocation mechanisms have been sharply criticised. In 
the UK, for instance, some argued that health workers 
ought to have been prioritised, and in the USA, there 
have been allegations that certain groups, such as univer-
sity or marketing staff in healthcare settings, were prior-
itised inappropriately.7 The question of overlapping 
vulnerabilities plagues most national allocation systems. 
For instance, in the USA, a subgroup of the Centers for 
Disease Control and Prevention’s Advisory Committee 
on Immunization Practices (ACIP) developed a five- tier 
prioritisation scheme, which borrowed interim allocation 
groups from a previous influenza pandemic vaccination 
plan. The full ACIP committee raised concerns about the 
vague nature of the tiers and questioned how the criteria 
would address race and ethnicity, low- income popula-
tions and pregnant women.8
When the H1N1 vaccine was allocated, decisions to 
prioritise vulnerable groups, such as prisoners and obese 
people, were met with hostility by some members of the 
public who were not prioritised for vaccination.9 Public 
perceptions of fairness in relation to vaccine alloca-
tion are likely to be influenced by ‘social and economic 
inequalities, racially- biased health systems, and a politi-
cized pandemic environment’ in the absence of clear 
and transparent communication of vaccine allocation 
processes and the evidence behind them.10
HOW HUMAN RIGHTS PRINCIPLES CAN INFORM VACCINE 
ALLOCATION IN PANDEMIC CONDITIONS
Early in the COVID-19 pandemic, the United Nations 
(UN) stipulated that a COVID-19 vaccine ‘should be 
provided without discrimination’, and acknowledged 
that ‘the human rights- based approach’ is an ‘effec-
tive pathway in the prevention of major public health 
threats’.11 The higher rates of severe COVID-19 illness 
Table 1 Four schemes of vaccine allocation
Global models Bioethics models
COVAX fair allocation mechanism
This mechanism relates to the distribution of COVID-19 
vaccines to countries on the basis of vulnerability according 
to three criteria:
 ► The number of front- line health workers.
 ► The proportion of people over the age of 65.
 ► The number of comorbidities in the country.
Nuffield Council on Bioethics
This proposal offers an ‘ethical compass’ of three broadly shared 
values in determining allocation of scarce resources during the 
pandemic:
 ► Ensuring equal respect, dignity and human rights.
 ► Helping to reduce suffering of those who are sick or otherwise 
in need.
 ► Maintaining fairness through both non- discriminatory 
treatment of others and equitable distribution of benefits and 
burdens.
WHO/SAGE values framework
The overarching goal of this framework is ‘for COVID-19 
vaccines to contribute significantly to the equitable 
protection and promotion of human well- being among all 
people of the world’, and human rights are recognised as 
key guiding principles.
Fair Priority Model5
This model is underscored by three fundamental values:
 ► Benefiting people and limiting harm.
 ► Prioritising the disadvantaged.
 ► Equal moral concern.
It focuses on three types of harms:
 ► Harm to individual health.
 ► The increased strain on healthcare systems, and the impact it 
has on particular health conditions.
 ► Global socioeconomic harm.
Vaccines should be allocated in three phases, prioritising the 
prevention of more urgent harms in earlier phases.
 on D
ecem









ealth: first published as 10.1136/bm





Sekalala S, et al. BMJ Global Health 2021;6:e004462. doi:10.1136/bmjgh-2020-004462 3
BMJ Global Health
and mortality among some systemically disadvantaged 
populations (eg, Black, Asian, and minority ethnic and 
Latinx communities, Indigenous people and refugees) 
provide a compelling case for determining how vulnera-
bilities are embedded in structural inequities that affect 
health. Justice requires that disparities in health risk 
and adverse outcomes across systemically disadvantaged 
groups be addressed in the collective COVID-19 response, 
including in the design of vaccine prioritisation schemes.
International human rights law provides a universal 
framework for advancing global health with justice, 
transforming moral imperatives into legal entitlements. 
Box 112 13 Every state has signed at least one human rights 
treaty and there is empirical evidence that all states have 
to some extent internalised human rights norms into 
legislation, policy and governance, even where compli-
ance with such norms is demonstrably lacking.14 15 
Here we argue that human rights legal principles have 
the potential to guide a more equitable allocation of a 
COVID-19 vaccine.16 A human rights approach reframes 
commitments as obligations and rights, and imposes 
accountability measures on states. International human 
rights law enshrines a range of individual and collec-
tive rights related to access to an essential vaccine for 
pandemic prevention (see Box 2).
Several vaccines for COVID-19 are already authorised 
in numerous countries.17 However, most countries will 
not immediately have the requisite number of vaccines 
for the entire population and so will have to make deci-
sions about who they should prioritise.18 Article 12 of the 
International Covenant on Economic, Social and Cultural 
Rights states that states have obligations to prevent and 
control epidemics.19 In General Comment No 14, which 
interprets states’ obligations under the right to health, 
the UN Committee on Economic, Social and Cultural 
Rights (CESCR) has stated that the provision of vaccines 
would be critical to fulfilling this objective.20 (See box 1 
for how these rights relate to access to a vaccine for 
pandemic prevention.) The Committee has also firmly 
positioned the provision of essential medicines defined 
by WHO as a ‘core obligation’ under the right to health. 
Such obligations are defined in General Comment No 3 
as the minimum standards that must be met by states to 
give meaning to the enjoyment of Covenant rights.21–23 
Therefore, providing a COVID-19 vaccine would fall 
within the core minimum obligations of states under the 
right to health, making it a priority.
Human rights frameworks insist that allocation decisions 
(including those for vaccines) meet some core minimum 
thresholds. This has been dubbed the availability, accessibility, 






UK 2 December 2020 Pfizer- 
BioNTech
 ► Residents in a care home for older adults and their carers.
 ► 80 years of age and over and front- line health and social care workers.
 ► 75 years of age and over.
 ► 70 years of age and over and clinically extremely vulnerable individuals.
 ► 65 years of age and over.
 ► 16–64 years with underlying health conditions which put them at higher risk of 
serious disease and mortality.
 ► 60 years of age and over.
 ► 55 years of age and over.
 ► 50 years of age and over42 (age related).
USA 11 December 2020 Pfizer- 
BioNTech
Phase 1a: Healthcare personnel and long- term care facility residents.
Phase 1b: Front- line essential workers and people aged 75 and older (front- line 
workers, elderly).
Phase 1c: People aged 65–74, people aged 16–64 with high- risk conditions, and 
other essential workers; and (high- risk groups).
Phase 2: People aged 16 and older not in phase 143 (rest of adult population).
Canada 9 December 2020 Pfizer- 
BioNTech
Stage 1: Residents and staff of congregate living settings that provide care for 
seniors; and (care workers).
Stage 2: Healthcare workers not included in the initial roll- out, residents and staff 
of all other congregate settings (eg, quarters for migrant workers, correctional 
facilities, homeless shelters) and essential workers44 (healthcare workers).
Russia August 2020 Sputnik- V The initial vaccination programme was reportedly offered to employees in Moscow 
aged 18–60 who work in schools and the health service, and social workers45 
(geographical focus: school staff, healthcare workers).
Israel No Pfizer- 
BioNTech
After healthcare workers and first responders, and people aged 60 and older, the 
next population group to receive the vaccine will be people in high- risk groups46 
(healthcare workers, elderly then high- risk groups).
The table only includes countries that had begun vaccination and have publicly available data as of the 22 December 2020.
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acceptability and quality (AAAQ) standard—see box 3. Addi-
tionally, the WHO has recently considered the question of 
prioritisation in the context of universal health coverage.22 
Three principles were used which are embedded in the right 
to health: fair distribution (priority services are based on 
need and priority is given to the worst- off groups (as discussed 
under the AAAQ)), cost- effectiveness and fair contribution 
(contributions based on ability to pay, not need).
The CESCR’s statements in the early stages of the 
pandemic, that ‘States must make every effort to mobilize 
the necessary resources to combat COVID-19 in the most 
equitable manner, in order to avoid imposing a further 
economic burden on these marginalized groups’ and that 
‘Allocation of resources should prioritize the special needs of 
these groups’,24 support a human rights- compliant approach 
to vaccine allocation. General Comment No 3 takes account 
of state resource constraints in the fulfilment of minimum 
core obligations. Thus, the issue of prioritisation becomes 
doubly important if a country’s available resources must be 
considered, as is the case with most low and middle- income 
countries. The efficient allocation of available resources 
necessitates that states consider value for money, meaning 
that given similar efficacy, states choose the cheapest vaccine 
available on the market. Given the many varied vaccines 
being offered at different prices,25 states must ensure that 
vaccine candidates that have particular expensive require-
ments (such as refrigeration) should not be prioritised in 
circumstances where there are poor resource constraints. 
States also have obligations to pool resources to buy vaccines 
more cheaply so as to benefit more people (see box 1).
Although human rights law tends to focus on universal 
access, there have been attempts to use human rights to 
conceptualise what equitable access ought to look like when 
resources are limited.26 For instance, in prioritising AIDS 
funding, scholars have called for an approach based on inter-
sectional vulnerabilities as a way of prioritising how groups 
are represented and allocated resources.27 This is particularly 
important where these vulnerabilities are linked to under-
lying determinants of health.
USING AN INTERSECTIONAL APPROACH TO CONSIDER 
UNDERLYING DETERMINANTS OF HEALTH WITHIN THE HUMAN 
RIGHTS REGIME
Intersectionality has come to shape the practice of UN 
Human Rights bodies, becoming a ‘major theme within 
Box 1 Human rights related to access to an essential 
vaccine for pandemic prevention
Right to health
States should take actions to translate the right to health, as 
articulated in the International Covenant on Economic, Social and 
Cultural Rights (ICESCR), into practice.47 For a pandemic vaccine, 
these steps include making it available in sufficient quantity, and 
distributing it in priority to people who are more likely to contract 
COVID-19, those whose health is at higher risk of being seriously 
compromised by COVID-19 and also those who may be most likely to 
transmit the virus. This entails ensuring non- discriminatory access to 
a vaccine.
Right to life
The universal right to life is enshrined in the International Covenant 
on Civil and Political Rights (ICCPR, Article 6). Its monitoring body, the 
United Nations Human Rights Committee, has recognised that state 
obligations under this right extend to ensuring universal access to 
essential medicines.48
Right to benefit from scientific progress
The right to enjoy the benefits of scientific progress and its applications is 
enshrined in the International Covenant on Economic Social Cultural Rights 
(ICESCR) (Article 15). The Committee on Economic Social and Cultural 
Rights (CESR) has indicated that the ‘right to science’ includes a duty to the 
equitable distribution of scientific advances, especially for vulnerable and 
marginalised populations.49
Box 2 Availability, accessibility, acceptability and quality 
(AAAQ) explained
According to the highly authoritative interpretation of the 
right to health in General Comment No 14, a COVID-19 
vaccine should be:
 ► Available in sufficient quantity, and in the absence of sufficient 
quantities, priority should be given to people who are more likely 
to contract the disease and those whose health is at higher risk of 
being seriously compromised to it.
 ► Affordable for all.
 ► Distributed so as to be respectful of transparency requirements and 
key medical ethics concepts, such as patients’ protection, consent 
and confidentiality.
 ► Safe and of good quality.23
 ► Provided without discrimination, especially to the most vulnerable 
and marginalised groups. The term vulnerability can be seen as in-
cluding elderly people, people with comorbidities that predispose 
them to poorer health outcomes, people in settings like prisons and 
group homes, marginalised and minority groups, and healthcare 
workers who are particularly at risk of infection. Equitable distribu-
tion within these minimum core obligations has been interpreted to 
include duties to reduce substantive inequalities such as socioeco-
nomic differences and other forms of disadvantage.50 In the next 
section, we discuss how an intersectional approach can ensure a 
more equitable and non- discriminatory distribution under human 
rights law.
Box 3 Intersectionality and Public Health
What is intersectionality?
Intersectionality is a theoretical framework for understanding how 
multiple social identities such as race, gender, sexual orientation, 
socioeconomic status and disability intersect at the micro level of 
individual experience to reflect interlocking systems of privilege and 
oppression.51
Intersectionality and public health
Public health scholars are increasingly using intersectionality to 
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the wider topic of discrimination’ to define and prioritise 
the most vulnerable and marginalised groups of people.28
In several places, human rights law refers to multiple 
grounds of discrimination, which have more than an 
additive effect on individuals, even though the term 
‘intersectionality’ is not used explicitly. The Conven-
tion on the Rights of the Child contains protections 
for children with disabilities (Article 23) and refugee 
children (Article 22), the Convention on the Rights 
of Persons with Disabilities specifically mentions 
that women with disabilities are subject to multiple 
discrimination (Article 6(1)), and the preamble of 
the Convention on the Elimination of All Forms of 
Discrimination Against Women (CEDAW) recognises 
the issues of race and poverty that affect women. In its 
work on prioritisation for universal health coverage, 
the WHO also specifically recognises that multiple 
characteristics based on social practices may help 
states to prioritise those most in need.29
Additionally, the UN Committees which give norma-
tive guidance to the treaties have referred to intersection-
ality. The CESCR noted that discrimination may occur on 
‘multiple grounds’, and in 2016, the CESCR further demon-
strated the intersectional nature of underlying determinants 
of health by highlighting ‘intersectional discrimination’ and 
‘intersecting forms of discrimination’.23 The CEDAW, in its 
General Recommendation No 28 on the Core Obligations 
of State Parties under Article 2, specifically recognises the 
intersectional harms on women due to discrimination based 
on race, ethnicity, religion or belief, health status, age, class, 
caste, sexual orientation and gender identity.30
The recommendations and statements issued by inter-
national human rights bodies in the context of COVID-19 
also acknowledge the intersectional effects of the pandemic 
among vulnerable groups, such as migrants, women, chil-
dren, people with disabilities, older people and front- line 
workers.31–35
The potential value of an intersectional model is illustrated 
in figure 1 in the simple case of two demographic vari-
ables: age and socioeconomic status (SES). For additional 
simplicity, in this discussion we treat SES as a three- level vari-
able (low, medium, high), but the argument is the same if 
SES is measured on a finer scale, or even on a continuous 
scale, and if more than two variables are included. Similarly, 
we use linear relationships here to show schematically the 
general features of the models.
In the simplest possible case (figure 1A,B), neither variable 
contributes to the model, and vaccine prioritisation is inde-
pendent of age or SES. In figure 1C,D, we see vaccine prior-
itisation dependent on each variable separately, with higher 
age resulting in higher vaccine prioritisation (figure 1C) 
and lower SES resulting in higher vaccine prioritisation 
(figure 1D). Figure 1C, in which priority depends only on 
age, is the current model in use in England. A more sophis-
ticated multivariable model allows both variables (age and 
SES) to influence vaccine prioritisation. In figure 1E, this is 
cumulative: the increase in prioritisation from age 50 to 60, 
for example, is the same, regardless of the SES of the person. 
Figure 1 Six schematic models of vaccine prioritisation. SES, socioeconomic status.
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Once we have given an increase in priority for being low SES, 
we operate as though we have taken account of SES, and do 
not consider it again. However, in an intersectional model, 
as shown in figure 1F, the variables age and SES interact, 
meaning that the increase in prioritisation from age 50 to 
60, for example, is greater for low SES people than it is for 
medium SES people. This reflects the way in which being 
older matters more for a lower SES person than it does for 
a higher SES person. A low SES person is likely to have a 
lower life expectancy and is effectively aged beyond their 
years, due to their relatively greater deprivation, worse access 
to healthcare, and so on. An intersectional model, as shown 
in figure 1F, attempts to account for that by increasing the 
prioritisation for a low SES person as they age beyond what a 
non- intersectional model would do.
PRIORITISING COVID-19 VACCINES BASED ON 
INTERSECTIONAL HUMAN RIGHTS NEEDS
A human rights- inspired focus on intersectional vulnerabil-
ities in vaccine allocation would recognise epidemiological 
factors as one of the elements of vulnerability but should 
also include other axes of discrimination that make groups 
vulnerable.36 This is defined by the WHO as those who are 
relatively disadvantaged with respect to health prospects, 
outcomes and SES, and captures the social determinants 
of health. This approach is emancipatory in that it seeks to 
improve the health outcomes of these groups in the short 
term while also aiming to redress underlying health inequi-
ties that have contributed to their discrimination in the first 
place. A human rights intersectional approach would require 
national actors to prioritise vaccine allocation to minority 
groups who simultaneously face different kinds of discrim-
ination on the basis of up- to- date and disaggregated civil 
registration, vital statistics and health data.37 This approach 
would complement deliberative approaches to bioethical 
models that apply similar values, but with the added benefit 
of normativity derived from the human rights framework.
Although some states may be tempted to charge 
for a vaccine because there is overwhelming need, the 
COVID-19 vaccine should be free at the point of access. 
Therefore, states with multitiered insurance schemes 
should ensure that they work collectively to ensure that 
those without insurance (eg, migrants) are prioritised as 
they will be among the categories that fit the intersec-
tional requirements identified above.
People experiencing socioeconomic conditions which 
make the spread of the contagion more likely should be 
identified using models which rely on epidemiological 
markers and on other vulnerabilities due to social determi-
nants of health. The UK model t, for instance, focused only 
on age at the beginning of the vaccination process, although 
(see figure 1C and table 2). By additionally including vari-
ables such as income, education, occupation, gender, race/
ethnicity, which shape specific determinants of health status, 
vaccine prioritisation frameworks could better conform 
to the human rights principle of non- discrimination and 
temper political agendas when decisions to prioritise vulner-
able groups for a vaccine are perceived to be unpopular.
In order to make these hard decisions, a human 
rights approach requires that states pay attention to 
procedural fairness around how decisions were made. 
Thus, the process should be transparent, participa-
tory to the greatest extent possible during a crisis 
and should involve accountability. Allocation deci-
sions (eg, the parameters of an intersectional model, 
such as the appropriate slopes of the lines) should 
be accompanied by a transparent national justifica-
tion for these decisions.38 Given the time constraints, 
there may be other ways of organising participation, 
such as involving civil society activists/social justice 
groups, that would give legitimacy to the process.
CRITERIA FOR PRIORITISATION OF COVID-19 VACCINATION
In building a model, we adapt the prioritisation criteria spec-
ified by the WHO in achieving universal health coverage, 
described above.39 We suggest three health- related criteria: 
increasing vulnerability to infection, social vulnerability 
that prioritises the worse off and financial and social risk 
protection (see box 4). We suggest prioritising people or 
groups who meet multiple criteria. This intersectional stance 
goes beyond a cumulative prioritisation (ie, adding a fixed 
number of points for each additional category), as we illus-
trated in figure 1E,F. In order to do this, decisions would have 
to be made about the levels of disadvantage due to the inter-
sectional harms that individuals face within different country 
Box 4 Criteria for prioritisation of COVID-19 vaccination*
Infection risk and severity of disease criteria: criteria related 




Criteria related to social vulnerabilities: criteria related to 
sociodemographic factors increasing the vulnerability
 ► Socioeconomic status.
 ► High- risk occupation: for example, healthcare workers, other front- 
line staff, delivery workers, garbage collection workers.
 ► Housing and living conditions: for example, crowded places, limited 
access to clean water and sanitation facilities.
 ► Place where one lives: for example, prisons, group homes for peo-
ple with disabilities, homeless people, nursing homes or longer 
term care facilities, refugee settlements.
 ► Gender, race, ethnicity, religion and sexual orientation- related fac-
tors that lead to stigma and limit access to healthcare.
Criteria related to protection against the financial and social 
effects of ill health
 ► Caring responsibilities.
 ► Catastrophic health and other expenditures if individuals get 
infected.
*The criteria are based on the analysis by Norheim et al40.
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settings, requiring greater representation and transparency 
about the decision- making processes.
ADOPTING AN INTERSECTIONAL HUMAN RIGHTS APPROACH 
TO VACCINE PRIORITISATION: THE CHALLENGES
As seen in figure 1, an intersectional human rights prioriti-
sation process would be more administratively complex and 
more expensive to run than a system that relies on single 
variables, and such a process might be slower. Adopting an 
intersectional approach would also involve making concrete 
distinctions about some vague concepts, such as race or 
ethnicity. Due to the intersecting nature of many social 
variables, intersectional categories are not always clear- cut, 
and states may struggle to identify people who do not fall 
neatly into set categories. There would also be incentives for 
privileged people to try to game the system so as increase 
their prioritisation, but this problem exists with any model, 
as older people, for instance, can move to countries which 
prioritise age more. (See box 4)
Creating models for prioritisation may be complex, 
given that most public health statistical methods have not 
been intersectional. Some scholars recognise that while 
existing statistical methods of analysing social data may 
pose a methodological challenge, given the ‘complex 
tenets of intersectionality’, and ‘more qualitative method-
ologies are critically needed’ to address such complexity, 
it is not necessary for public health scholars and policy-
makers to wait for such challenges to be resolved prior 
to incorporating intersectionality into public health 
interventions.40 41 Additionally, transparent and partici-
patory approaches which involve individuals and experts 
who have studied those social categories can help states 
to determine priority categorisations. We recognise that 
participation with all affected groups may not be possible, 
but human rights regimes have a long tradition of using 
civil society organisations and cross- sectional representa-
tion to engender participation.
Politically, an intersectional approach which prioritises 
minority groups may be unpopular with some. However, 
as the proponents of intersectionality argue, it was always 
meant to be a political project, and if it is grounded in a 
human rights approach, using the best scientific evidence 
and making attempts at redistribution, courts will struggle 
to overturn decision- making processes that are procedur-
ally correct. This approach, which deals with historically 
oppressed or marginalised populations, could be used as 
a springboard to facilitate and inform the development 
of other health interventions. As we have seen from the 
COVID-19 crisis, health outcomes are interlinked with 
social vulnerabilities, because we rely on the most socially 
vulnerable groups to run our economies. Thus, adopting 
an intersectional human rights approach to COVID-19 
vaccine allocation would be an opportunity to shape a 
more just and equitable society.
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